[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-331300-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-331300-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","ddr1-is-a-novel-biomarker-and-potential-therapeutic-target-for-the-combination-treatment-of-liver-hepatocellular-carcinoma-article","DDR1 is a Novel Biomarker and Potential Therapeutic Target for the Combination Treatment of Liver Hepatocellular Carcinoma - Article","","Aim: Investigate the role of discoidin domain receptor tyrosine kinase 1 (DDR1) in liver hepatocellular carcinoma (LIHC) and assess its prognostic value for patient response to combination therapy. Methods: A retrospective study measured DDR1 protein expression across cancers using standard immunohistochemistry (IHC) and evaluated clinical significance in LIHC personalized treatment. Data from TCGA, TIMER, GEO, ROC Plotter, and GDSC supported analyses of expression patterns and treatment relevance. Results and conclusions: DDR1 is higher in LIHC, links to sorafenib resistance, correlates with inflammatory/ECM and reduced immune infiltration, and suggests prognostic and therapeutic potential.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/ddr1-is-a-novel-biomarker-and-potential-therapeutic-target-for-the-combination-treatment-of-liver-hepatocellular-carcinoma-article/331300/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/ddr1-is-a-novel-biomarker-and-potential-therapeutic-target-for-the-combination-treatment-of-liver-hepatocellular-carcinoma-article/331300.png","ImageObject",300,407,{"name":42,"@type":43},"Levi","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-06","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main purpose of this study on DDR1 in liver hepatocellular carcinoma (LIHC)?","Question",{"text":63,"@type":64},"To clarify DDR1’s role in LIHC and determine whether DDR1 has prognostic value for how patients respond to combination therapy.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was DDR1 expression measured and evaluated in the study?",{"text":68,"@type":64},"DDR1 protein expression was assessed using standard immunohistochemical (IHC) methods in a retrospective analysis, with support from multiple online databases including TCGA, TIMER, GEO, ROC Plotter, and GDSC.",{"name":70,"@type":61,"acceptedAnswer":71},"What findings connect DDR1 with treatment resistance and immune status in LIHC?",{"text":72,"@type":64},"DDR1 upregulation correlated with sorafenib resistance, showed positive association with inflammatory response and ECM/collagen-related genes, and was negatively correlated with infiltration of CD8+ T cells, NK cells, and dendritic cells in LIHC.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},331300,1790012848,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":107,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":4},7971461740909,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","DDR1 is a Novel Biomarker and Potential Therapeutic Target for the Combination Treatment of Liver Hepatocellular Carcinoma  \nCancer Control Volume 31: 1–7  \n© The Author(s) 2024  \nArticle reuse guidelines:  \n[sagepub.com/journals-permissions](sagepub.com/journals-permissions)  \n[DOI: 10.1177/10732748241286257](DOI: 10.1177/10732748241286257)[ ](DOI: 10.1177/10732748241286257)[journals.sagepub.com/home/ccx](journals.sagepub.com/home/ccx)  \nTianxing Li 1,2,*, Hao Hu3,*, Yuhao Song2, Yihai Shi4, Dingtao Hu 1, Weifeng Shen5, and Beifang Ning2 􀀁  \nAbstract  \nAim: This study aimed to investigate the role of discoidin domain receptor tyrosine kinase 1 (DDR1) in liver hepatocellular carcinoma (LIHC) and to evaluate its prognostic value on patient response to combination therapy.  \nMethods: In the current retrospective study, we examined the protein expression of DDR1 in various cancers by standard immunohistochemical (IHC) methods and evaluated its clinical significance in LIHC personalized treatment. Multiple online databases, including The Cancer Genome Atlas (TCGA), TIMER, GEO, ROC Plotter, and Genomics of Drug Sensitivity in Cancer (GDSC), were used.  \nResults: DDR1 protein expression was higher in LIHC than in other nine examined cancer types. Additionally, DDR1 exhibited higher expression levels in adjacent normal tissues compared to HBs-positive LIHC tissues. Analysis at single-cell resolution revealed that DDR1 was expressed primarily in epithelial cells but not in stromal and immune cells, and DDR1 expression was lower in HBs-positive LIHC cells in comparison with normal hepatocytes. Correlation of DDR1 upregulation and sorafenib resistance was observed in the patient cohort. Moreover, DDR1 expression positively correlated with the expression of inflammatory response-related genes, ECM-related genes, and collagen formation-related genes, but negatively correlated with the infiltration of CD8+ T cells, NK cells, and dendritic cells in LIHC.  \nConclusions: Our findings suggest that DDR1 expression might be induced by collagen production-related cellular events involved in liver injury and repair, and that DDR1 overexpression might contribute to the resistance to LIHC targeted therapy and immunotherapy, highlighting DDR1 as a potential prognostic biomarker and therapeutic target.  \n1 Clinical Cancer Institute, Center for Translational Medicine, Naval Medical University, Shanghai, China 2Department of Gastroenterology, Changzheng Hospital, Naval Medical University, Shanghai, China 3Department of Pathology, Changhai Hospital, Naval Medical University, Shanghai, China 4Department of Gastroenterology, Shanghai Pudong New Area Gongli Hospital, Shanghai, China  \n5The Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, China  \n*These authors contributed equally to this work.  \nCorresponding Authors:  \nDingtao Hu, MD, Clinical Cancer Institute, Center for Translational Medicine, Naval Medical University, Shanghai 200433, China.  \nEmail: [hdt1500865192@163.com](hdt1500865192@163.com)  \nWeifeng Shen, MD, The Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, 800 Xiangyin Road, Shanghai 200433, China.  \nEmail: [docshenweifeng@163.com](docshenweifeng@163.com)  \nBeifang Ning, MD, Department of Gastroenterology, Changzheng Hospital, Naval Medical University, Shanghai, China.  \nEmail: [ningbeifangsmu@163.com](ningbeifangsmu@163.com)  \nCreative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons  \nAttribution-NonCommercial 4.0 License ([https://creativecommons.org/licenses/by-nc/4.0/](https://creativecommons.org/licenses/by-nc/4.0/)) which permits non-commercial use,  \nreproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages ([https://us.sagepub.com/en-us/nam/open-access-at-sage](https://us.sagepub.com/e","cbCaibUVXNon5hLT","https://ap.wps.com/l/cbCaibUVXNon5hLT","pdf",901290,"English","# Abstract\n## Aim\n## Methods\n## Results\n## Conclusions\n# Plain Language Summary\n# Keywords\n# Funding and Licensing","[{\"question\":\"What is the main purpose of this study on DDR1 in liver hepatocellular carcinoma (LIHC)?\",\"answer\":\"To clarify DDR1’s role in LIHC and determine whether DDR1 has prognostic value for how patients respond to combination therapy.\"},{\"question\":\"How was DDR1 expression measured and evaluated in the study?\",\"answer\":\"DDR1 protein expression was assessed using standard immunohistochemical (IHC) methods in a retrospective analysis, with support from multiple online databases including TCGA, TIMER, GEO, ROC Plotter, and GDSC.\"},{\"question\":\"What findings connect DDR1 with treatment resistance and immune status in LIHC?\",\"answer\":\"DDR1 upregulation correlated with sorafenib resistance, showed positive association with inflammatory response and ECM/collagen-related genes, and was negatively correlated with infiltration of CD8+ T cells, NK cells, and dendritic cells in LIHC.\"}]","DDR1 is a Novel Biomarker and Potential Therapeutic Target for the Combination Treatment of Liver Hepatocellular Carcinoma - Article | PDF",1789992581,18]